Skip to main content

Security report for jpnpharma.net

JPN Pharma · Healthcare · India

High risk. 9 critical or high findings in Security headers, GDPR outside view and 2 other checks.

Security score

44/100

Risk levelHigh

0–100, higher is better. How it is calculated

JPN Pharma Pvt. Ltd. is a well-established pharmaceutical manufacturer based in India, specializing in the production of Active Pharmaceutical Ingredients (APIs) and drug intermediates since 1990. The company has a strong market presence with exports to over 52 countries and holds multiple certifications such as CEP and DMF, indicating compliance with international pharmaceutical standards. Their website reflects a professional and consistent brand image, targeting pharmaceutical companies and healthcare industry professionals globally. Technically, the website is built on WordPress using modern page builders like Elementor and WPBakery, with SEO optimization via Yoast SEO and integration of Google Analytics for tracking. The site is mobile-optimized and performs moderately well, though accessibility features could be improved. Security posture is adequate with HTTPS enabled, but lacks explicit security headers and formal security policies. The absence of WHOIS data for the domain raises concerns about domain registration legitimacy, which impacts trustworthiness despite the professional presentation. No privacy or cookie policies were found, indicating potential compliance gaps with GDPR and other privacy regulations. Contact information is clearly provided, including emails, phone numbers, and physical addresses for multiple plants. Overall, JPN Pharma demonstrates a solid business and technical foundation but should address domain registration transparency and privacy compliance to enhance trust and security posture.

Scanned

NIS2 and GDPR posture

GDPR outside view
35/ 100 · High
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

9 findings rated critical or high. Fix these first.

  1. Security headers

    Security headers are instructions your web server sends to every visitor’s browser. Missing ones leave visitors more exposed to attacks such as clickjacking and injected scripts.

    • High

      Missing Strict-Transport-Security header

      Forces HTTPS connections

      What to do: Add "Strict-Transport-Security: max-age=31536000; includeSubDomains; preload"

      • CWE-319
      • OWASP A04:2025
      • ASVS V3.4.1
    • High

      Missing X-Frame-Options header

      Prevents clickjacking attacks

      What to do: Add "X-Frame-Options: DENY" or "X-Frame-Options: SAMEORIGIN"

  2. GDPR outside view

    These are the privacy signals visitors and data protection authorities look for under GDPR.

    • High

      No Privacy Policy found

      GDPR requires a clear and accessible privacy policy

      What to do: Add a comprehensive privacy policy page and link to it prominently

    • High

      No Cookie Policy found

      GDPR requires clear information about cookie usage

      What to do: Add a dedicated cookie policy explaining cookie usage and purposes

    • High

      No Cookie Consent Banner found

      GDPR requires explicit consent for non-essential cookies

      What to do: Implement a cookie consent banner that appears on first visit

Need hands-on remediation? Email guard@offseq.com

Keep watching jpnpharma.net

This scan found 28 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. The full timeline opens with your unlock code.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
27
Security headers
30
Email security
75
DNS health
75
Network security
20
GDPR outside view
35
Average
44

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

JPN Pharma operates in the healthcare and manufacturing sectors, focusing on pharmaceutical APIs and intermediates. Their business model is B2B, supplying pharmaceutical companies worldwide. The company leverages its long-standing industry experience since 1990 and certifications to maintain competitive advantage. Their partnership with entities like Shri Vinayak Chemex indicates a collaborative ecosystem. The website's content and client logos suggest a reputable market position with major pharmaceutical clients. Growth indicators include a broad export footprint and multiple manufacturing plants. Revenue streams likely derive from API and intermediate sales. The company targets pharmaceutical manufacturers and healthcare providers, emphasizing quality and compliance.

Security posture

The website employs HTTPS, ensuring encrypted communications. However, it lacks explicit security headers such as Content-Security-Policy, X-Frame-Options, and X-Content-Type-Options, which are recommended to mitigate common web vulnerabilities. No incident response or vulnerability disclosure policies are present, limiting transparency in security management. The absence of privacy and cookie policies suggests compliance gaps with GDPR and related regulations. No exposed sensitive data or vulnerable libraries were detected in the HTML content. Overall, the security maturity is moderate but could be significantly improved by implementing recommended headers, formal policies, and regular security audits.

Recommendations

  1. Register and verify domain WHOIS information to improve legitimacy and trust.
  2. Publish comprehensive privacy and cookie policies with explicit user consent mechanisms.
  3. Implement security headers including Content-Security-Policy, X-Frame-Options, and X-Content-Type-Options.
  4. Establish an incident response and vulnerability disclosure page to enhance security transparency.
  5. Enhance website accessibility features to comply with standards and improve user experience.

Contact details published on the site

Addresses
Legal name
JPN Pharma Pvt. Ltd.
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
JPN Pharma
Description
Since 1990, JPN Pharma has been a leading name in the pharmaceutical industry. Based in India, they are a premier vertically integrated manufacturer of Active Pharmaceutical Ingredients (APIs) and drug intermediates.
Key services
Manufacturing of APIs, Manufacturing of Drug Intermediates, Supply chain management for pharmaceutical ingredients
Content quality
good
Branding
consistent

Technology

Stack
WordPress, Elementor, WPBakery Page Builder, Slider Revolution, jQuery, Google Fonts, Swiper.js
Frameworks
Yoast SEO
Platforms
WordPress CMS
Performance
moderate
Mobile
good
Accessibility
basic
SEO
good

Security

Observed score
75/100
Good practices seen
  • HTTPS enabled
  • No exposed sensitive data in HTML
  • Use of security plugins (implied by WordPress ecosystem)

Analytics and tracking

Services
Google Analytics
Tracking level
moderate
Privacy practices
basic

Advertising

Tracking pixels
Google Analytics (via gtag.js)
Transparency
basic

Site quality

Design
good
User experience
good
Content relevance
good
Navigation
good
Professionalism
good
Trustworthiness
high

Key observations

  1. Website is a professional pharmaceutical manufacturer site with detailed product and company info.
  2. No privacy or cookie policies explicitly found on main page or footer.
  3. Contact info is clearly provided with emails, phone numbers, and physical addresses.
  4. WHOIS data is missing or domain not registered, which is a concern for legitimacy.
  5. No security or incident response policies found.
  6. Use of modern WordPress plugins and SEO tools.
  7. No adult or questionable content detected.
  8. Good branding consistency and trust signals from certifications and client logos.
Technical notes

Notes

The website is built on a WordPress CMS platform using popular page builders Elementor and WPBakery, combined with Slider Revolution for dynamic content. It uses modern JavaScript libraries such as jQuery and Swiper.js for interactive elements. SEO is managed via Yoast SEO plugin, and Google Analytics is integrated for visitor tracking. The site loads with moderate speed and is mobile responsive. However, there is room for improvement in accessibility and security header implementation. Hosting provider details are not explicitly found. The technical stack is mature but requires ongoing maintenance to ensure security and performance.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with jpnpharma.net. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review jpnpharma.net.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.